• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

根治性肾输尿管切除术治疗上尿路上皮癌患者的淋巴血管侵犯对肿瘤学结果的影响。

Impact of lymphovascular invasion on oncological outcomes in patients with upper tract urothelial carcinoma after radical nephroureterectomy.

机构信息

Department of Urology, Côte de Nacre Hospital, CHU Caen, Caen, France.

出版信息

BJU Int. 2013 Jun;111(8):1199-207. doi: 10.1111/bju.12116. Epub 2013 Apr 12.

DOI:10.1111/bju.12116
PMID:23650914
Abstract

OBJECTIVES

To assess the impact of lymphovascular invasion (LVI) on upper urinary tract urothelial carcinomas (UTUCs) in a multicentre study on cancer-specific survival (CSS), recurrence-free survival and metastasis-free survival (MFS). To show the negative impact of LVI for patients with pN0/x disease and to stratify these patients into risk groups for metastatic relapse.

PATIENTS AND METHODS

A multicentre retrospective study was performed on patients who underwent radical nephroureterectomy between 1995 and 2010. LVI status was evaluated as a prognostic factor for survival using univariate and multivariate Cox regression analysis.

RESULTS

Overall, 551 patients were included and were divided into two groups: those without LVI (LVI-), n = 388 and those with LVI (LVI+), n = 163. LVI+ status was associated with high stage and grade UTUC and lymph node metastasis (P < 0.001). The 5-year CSS and MFS rates were significantly worse in the LVI+ group than in LVI- group (52.2 vs 84.5%, P < 0.001 and 43.8 vs 82.7%, P < 0.001, respectively). In multivariate analysis, LVI+ status was an independent prognostic factor for CSS and MFS (P = 0.04 and P < 0.001). These findings were confirmed for the pN0/x patient subgroup (n = 504, P < 0.001). In the pN0/x patient subgroup, we described a prognostic tool for MFS based on independent factors that permitted us to stratify patients into groups of high, intermediate or low risk of metastasis relapse.

CONCLUSIONS

The presence of LVI was a strong predictor of a poor outcome for UTUC. When a lymphadenectomy has not been achieved, the report of LVI status is crucial to identfiy those patients at higher risk for metastatic relapse.

摘要

目的

在一项关于癌症特异性生存(CSS)、无复发生存和无转移生存(MFS)的多中心研究中,评估淋巴血管侵犯(LVI)对上尿路上皮癌(UTUC)的影响。为 pN0/x 疾病患者的 LVI 表现出负面影响,并将这些患者分层为转移复发的高危组。

患者和方法

对 1995 年至 2010 年间接受根治性肾输尿管切除术的患者进行了多中心回顾性研究。使用单变量和多变量 Cox 回归分析评估 LVI 状态作为生存的预后因素。

结果

共纳入 551 例患者,分为两组:无 LVI(LVI-)组 388 例,有 LVI(LVI+)组 163 例。LVI+状态与高分期和高分级 UTUC 以及淋巴结转移相关(P<0.001)。LVI+组的 5 年 CSS 和 MFS 率明显低于 LVI-组(52.2% vs 84.5%,P<0.001 和 43.8% vs 82.7%,P<0.001)。多变量分析显示,LVI+状态是 CSS 和 MFS 的独立预后因素(P=0.04 和 P<0.001)。这些发现在 pN0/x 患者亚组(n=504,P<0.001)中得到了证实。在 pN0/x 患者亚组中,我们描述了一种基于独立因素的 MFS 预后工具,该工具允许我们将患者分层为高、中或低转移复发风险组。

结论

LVI 的存在是 UTUC 预后不良的强烈预测因素。当未进行淋巴结切除术时,LVI 状态的报告对于确定那些转移复发风险较高的患者至关重要。

相似文献

1
Impact of lymphovascular invasion on oncological outcomes in patients with upper tract urothelial carcinoma after radical nephroureterectomy.根治性肾输尿管切除术治疗上尿路上皮癌患者的淋巴血管侵犯对肿瘤学结果的影响。
BJU Int. 2013 Jun;111(8):1199-207. doi: 10.1111/bju.12116. Epub 2013 Apr 12.
2
Prognostic indicators for upper tract urothelial carcinoma after radical nephroureterectomy: the impact of lymphovascular invasion.根治性肾输尿管切除术治疗上尿路上皮癌的预后指标:淋巴血管侵犯的影响。
BJU Int. 2012 Sep;110(6):798-803. doi: 10.1111/j.1464-410X.2011.10893.x. Epub 2012 Feb 7.
3
Comparison of oncological outcomes after segmental ureterectomy or radical nephroureterectomy in urothelial carcinomas of the upper urinary tract: results from a large French multicentre study.比较上尿路尿路上皮癌行节段性输尿管切除术与根治性肾输尿管切除术的肿瘤学结局:一项来自法国大型多中心研究的结果。
BJU Int. 2012 Oct;110(8):1134-41. doi: 10.1111/j.1464-410X.2012.10960.x. Epub 2012 Mar 6.
4
Lymphovascular invasion and pT stage are prognostic factors in patients treated with radical nephroureterectomy for localized upper urinary tract transitional cell carcinoma.在接受根治性肾输尿管切除术治疗局限性上尿路上皮细胞癌的患者中,淋巴血管侵犯和 pT 分期是预后因素。
Urology. 2010 Feb;75(2):328-32. doi: 10.1016/j.urology.2009.07.1350.
5
Clinical significance of lymphovascular invasion in upper urinary tract urothelial cancer.上尿路尿路上皮癌中淋巴管侵犯的临床意义
BJU Int. 2008 Aug 5;102(5):572-5. doi: 10.1111/j.1464-410X.2008.07749.x. Epub 2008 May 15.
6
Prognostic value of lymphovascular invasion in transitional cell carcinoma of upper urinary tract.上尿路移行细胞癌中淋巴管侵犯的预后价值
Urology. 2005 Apr;65(4):692-6. doi: 10.1016/j.urology.2004.11.001.
7
Impact of lymph node dissection on cancer specific survival in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy.淋巴结清扫术对接受根治性肾输尿管切除术治疗的上尿路尿路上皮癌患者癌症特异性生存的影响。
J Urol. 2009 Jun;181(6):2482-9. doi: 10.1016/j.juro.2009.02.021. Epub 2009 Apr 16.
8
Prognostic significance of lymphovascular invasion in upper urinary tract urothelial carcinoma is influenced by tumor location.上尿路尿路上皮癌中淋巴管侵犯的预后意义受肿瘤位置影响。
Ann Surg Oncol. 2015 Apr;22(4):1392-400. doi: 10.1245/s10434-014-4103-x. Epub 2014 Sep 20.
9
Impact of tumour location versus multifocality in patients with upper tract urothelial carcinoma treated with nephroureterectomy and bladder cuff excision: a homogeneous series without perioperative chemotherapy.在上尿路尿路上皮癌患者接受肾输尿管切除术和膀胱袖状切除术治疗中,肿瘤位置与多灶性的影响:无围手术期化疗的同质系列。
BJU Int. 2012 Jul;110(2 Pt 2):E7-13. doi: 10.1111/j.1464-410X.2011.10792.x. Epub 2011 Dec 16.
10
Oncological outcomes after laparoscopic and open radical nephroureterectomy: results from an international cohort.腹腔镜与开放根治性肾输尿管切除术的肿瘤学结果:国际队列研究结果。
BJU Int. 2011 Aug;108(3):406-12. doi: 10.1111/j.1464-410X.2010.09826.x. Epub 2010 Nov 15.

引用本文的文献

1
Assessing the Influence of Bladder Cancer on Upper Tract Urothelial Carcinoma Prognoses Following Radical Nephroureterectomy: A Retrospective, Propensity Score-Based Multicenter Cohort Study.评估根治性肾输尿管切除术后膀胱癌对上尿路尿路上皮癌预后的影响:一项基于倾向评分的回顾性多中心队列研究。
Ann Surg Oncol. 2025 Aug 25. doi: 10.1245/s10434-025-17808-6.
2
To explore the risk factors of lymphovascular invasion in patients with upper tract urothelial carcinoma and construct a prediction model.探讨上尿路尿路上皮癌患者淋巴管侵犯的危险因素并构建预测模型。
Front Oncol. 2025 Mar 25;15:1568774. doi: 10.3389/fonc.2025.1568774. eCollection 2025.
3
Upper Tract Urothelial Carcinoma (UTUC) Diagnosis and Risk Stratification: A Comprehensive Review.
上尿路尿路上皮癌(UTUC)的诊断与风险分层:综述
Cancers (Basel). 2023 Oct 14;15(20):4987. doi: 10.3390/cancers15204987.
4
Oncologic outcomes following radical nephroureterectomy for upper tract urothelial carcinoma: a literature review.上尿路尿路上皮癌根治性肾输尿管切除术后的肿瘤学结局:文献综述
Transl Androl Urol. 2023 Aug 31;12(8):1351-1362. doi: 10.21037/tau-22-882. Epub 2023 Jul 28.
5
Risk factors for extraurothelial recurrence in upper tract urothelial carcinoma after radical nephroureterectomy: a retrospective study based on a Chinese population.根治性肾输尿管切除术后上尿路尿路上皮癌发生尿外复发的危险因素:一项基于中国人群的回顾性研究
Front Oncol. 2023 Aug 9;13:1164464. doi: 10.3389/fonc.2023.1164464. eCollection 2023.
6
VCAN Hypomethylation and Expression as Predictive Biomarkers of Drug Sensitivity in Upper Urinary Tract Urothelial Carcinoma.VCAN 低甲基化和表达可作为上尿路上皮癌药物敏感性的预测生物标志物。
Int J Mol Sci. 2023 Apr 19;24(8):7486. doi: 10.3390/ijms24087486.
7
Impact of pathological factors on survival in patients with upper tract urothelial carcinoma: a systematic review and meta-analysis.影响上尿路尿路上皮癌患者生存的病理因素:系统评价和荟萃分析。
Int Braz J Urol. 2022 May-Jun;48(3):406-455. doi: 10.1590/S1677-5538.IBJU.2020.1032.
8
The Prognostic Value of Lymphovascular Invasion in Patients With Upper Tract Urinary Carcinoma After Surgery: An Updated Systematic Review and Meta-Analysis.上尿路尿路上皮癌患者术后淋巴管侵犯的预后价值:一项更新的系统评价和荟萃分析
Front Oncol. 2020 Apr 22;10:487. doi: 10.3389/fonc.2020.00487. eCollection 2020.
9
Significant clinicopathologic prognostic factors for bladder recurrence, progression, and cancer-specific survival after surgery among patients with upper urinary tract urothelial carcinoma.在上尿路尿路上皮癌患者手术后,膀胱癌复发、进展和癌症特异性生存的重要临床病理预后因素。
Investig Clin Urol. 2019 Nov;60(6):432-442. doi: 10.4111/icu.2019.60.6.432. Epub 2019 Oct 11.
10
Dataset for the reporting of urinary tract carcinoma-biopsy and transurethral resection specimen: recommendations from the International Collaboration on Cancer Reporting (ICCR).国际癌症报告协作组织(ICCR)关于泌尿道上皮癌活检和经尿道切除标本报告的数据集建议。
Mod Pathol. 2020 Apr;33(4):700-712. doi: 10.1038/s41379-019-0403-9. Epub 2019 Nov 4.